` HPHA (Heidelberg Pharma AG) vs DAX Index Comparison - Alpha Spread

HPHA
vs
DAX Index

Over the past 12 months, HPHA has underperformed DAX Index, delivering a return of -30% compared to DAX Index's +7% growth.

Stocks Performance
HPHA vs DAX Index

Loading...
HPHA
DAX Index
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
HPHA vs DAX Index

Performance Gap Between HPHA and GDAXI

Create a free account · No card needed

Performance By Year
HPHA vs DAX Index

Loading...
HPHA
DAX Index
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Heidelberg Pharma AG vs Peers

DAX Index
HPHA
ABBV
AMGN
GILD
VRTX
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Heidelberg Pharma AG
Glance View

Market Cap
96.9m EUR
Industry
Biotechnology

Heidelberg Pharma is a German biotechnology company focused on cancer drugs. It does not sell a consumer product; instead, it develops antibody-drug conjugates, or ADCs, that attach a toxic payload to an antibody so the medicine can target cancer cells more precisely. Its best-known work is based on its ATAC technology, which uses a toxin called amanitin. The company makes money in two main ways: by advancing its own drug candidates and by working with pharmaceutical partners on research and licensing deals. Partners pay for access to its technology, and the company can also earn milestone payments and royalties if those drug programs succeed. In that model, Heidelberg Pharma acts as a technology owner and drug developer rather than a large-scale drug manufacturer. For beginners, the key point is that Heidelberg Pharma sits in the early-to-mid stage of the cancer drug value chain. It sells scientific know-how, drug candidates, and platform access to other drug companies, while aiming to turn its own research into future medicines for patients with hard-to-treat cancers.

HPHA Intrinsic Value

Create a free account · No card needed

Back to Top